Insider Transactions in Q1 2025 at Lyell Immunopharma, Inc. (LYEL)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 21
2025
|
Sumant Ramachandra |
BUY
Open market or private purchase
|
Indirect |
200,000
+50.0%
|
$0
$0.58 P/Share
|
|
Mar 17
2025
|
Charles W. Newton Chief Financial Officer |
BUY
Open market or private purchase
|
Indirect |
200,000
+50.0%
|
$0
$0.56 P/Share
|
|
Mar 14
2025
|
Richard Klausner |
BUY
Open market or private purchase
|
Indirect |
158,000
+15.78%
|
$0
$0.6 P/Share
|
|
Mar 14
2025
|
Lynn Seely President and CEO |
BUY
Open market or private purchase
|
Direct |
175,000
+19.72%
|
$0
$0.61 P/Share
|
|
Feb 10
2025
|
Matthew Lang Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
112,500
+40.91%
|
-
|
|
Feb 10
2025
|
Stephen J. Hill Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
112,500
+39.42%
|
-
|
|
Feb 10
2025
|
Lynn Seely President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
337,500
+38.57%
|
-
|
|
Feb 10
2025
|
Gary K. Lee Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
112,500
+38.9%
|
-
|
|
Feb 10
2025
|
Charles W. Newton Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
112,500
+39.44%
|
-
|